Estrogen and progesterone regulate the IL-6 signal transduction pathway in antibody secreting cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 111, Issue 3-5, 2008, Pages 255-261

  Canellada, Andrea ^a   Alvarez, Irene ^a   Berod, Luciana ^a   Gentile, Teresa ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Estrogen; Hybridoma; Interleukin 6; PIBF; Progesterone; Signal transduction

Indexed keywords

ESTROGEN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; JANUS KINASE 1; PROGESTERONE; PROGESTERONE INDUCED BLOCKING FACTOR; PROTEIN; STAT3 PROTEIN;

ANTIBODY PRODUCING CELL; ARTICLE; CONCENTRATION RESPONSE; ESTROGEN ACTIVITY; HORMONAL REGULATION; HYBRIDOMA CELL CULTURE; IMMUNOREGULATION; NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODY-PRODUCING CELLS; CYTOKINE RECEPTOR GP130; ESTROGENS; FEMALE; INTERLEUKIN-6; JANUS KINASE 1; MICE; PREGNANCY; PREGNANCY PROTEINS; PROGESTERONE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 49449097808     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.06.009     Document Type: Article

References (57)

1. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int. Immunopharmacol. 1 (2001) 983-993
2. Piccinni M.P., Guidizi M.G., Biagiotti R., Beloni L., Giannarini L., Sampognaro S., Parronchi P., Manetti R., Annunziato F., Livi C., Romagnani S., and Maggi E. Progesterone favors the development of human T helper cells producing Th2 type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J. Immunol. 155 (1995) 128-133
3. Lim K.J.H., Odukoya O.A., Ajjan R.A., Li T.C., Weetman A.P., and Cooke I.D. Profile of cytokine mRNA expression in peri-implantation human endometrium. Mol. Hum. Reprod. 4 (1998) 77-81
4. Mowbray J.F., and Underwood J.L. Immunology of abortion. Clin. Exp. Immunol. 60 (1985) 1-7
5. Innes A., Cunningham C., Power D.A., and Catto G.R. Fetus as an allograft: noncytotoxic maternal antibodies to HLA-linked paternal antigens. Am. J. Reprod. Immunol. 19 (1989) 146-150
6. Malan Borel I., Gentile T., Angelucci J., Pividori J., and Margni R. IgG asymmetric molecules with anti-paternal activity isolated from sera and placenta of pregnant human. J. Reprod. Immunol. 20 (1991) 129-140
7. Mowbray J., Jalali R., Chaouat G., Clark D.A., Underwood J., Allen W.R., and Mathias S. Maternal response to paternal trophoblast antigens. Am. J. Reprod. Immunol. 37 (1997) 421-426
8. Jalali G.R., Rezai A., Underwood J.L., Mowbray J.F., Surridge S.H., Allen W.R., and Matthias S. An 80-kDa syncytiotrophoblast alloantigen bound to maternal alloantibody in term placenta. Am. J. Reprod. Immunol. 33 (1995) 213-220
9. Jalali G.R., Arck P., Surridge S., Markert U., Chaouat G., Clark D.A., Underwood J.L., and Mowbray J.F. Immunosuppressive properties of monoclonal antibodies and human polyclonal alloantibodies to the R80K protein of trophoblast. Am. J. Reprod. Immunol. 36 (1996) 129-134
10. Labeta M., Margni R., Leoni J., and Binaghi R. Structure of asymmetric non-precipitating antibodies. Presence of a carbohydrate residue in only one Fab region of the molecule. Immunology 57 (1986) 314-317
11. Leoni J., Labeta M., and Margni R.A. The asymmetric IgG non-precipitating antibody. Localization of the oligosaccharide involved by Concanavalin A interaction. Mol. Immunol. 23 (1986) 1397-1400
12. Pos O., Moshage H.J., Yap S.H., Snieders J.P., Aarden L.A., van Gool J., Boers W., Brugman A.M., and van Dijk W. Effects of monocytic products, recombinant interleukin-1, and recombinant interleukin-6 on glycosylation of alpha 1-acid glycoprotein: studies with primary human hepatocyte cultures and rats. Inflammation 13 (1989) 415-427
13. Mackiewicz A., Rose-John S., Schooltink H., Laciak M., Gorny A., and Heinrich P.C. Soluble human interleukin-6-receptor modulates interleukin-6-dependent N-glycosylation of alpha 1-protease inhibitor secreted by HeP42 cells. FEBS Lett. 306 (1992) 257-261
14. Gutierrez G., Malan Borel I., and Margni R.A. The placental regulatory factor involved in the asymmetric IgG antibody synthesis responds to IL-6 features. J. Reprod. Immunol. 49 (2001) 21-32
15. Margni R.A., and Zenclussen A.C. During pregnancy, in the context of a Th2-type cytokine profile, IL-6 levels might condition the quality of the synthesized antibodies. Am. J. Reprod. Immunol. 44 (2000) 22-29
16. Canellada A., Blois S., Gentile T., and Margni R.A. In vitro modulation of protective antibody responses by estrogen, progesterone and interleukin-6. Am. J. Reprod. Immunol. 48 (2002) 333-343
17. Kelemen K., Bognar I., Paal M., and Szekeres-Bartho J. A progesterone-induced protein increases the synthesis of asymmetric antibodies. Cell. Immunol. 167 (1996) 129-134
18. Kozma N., Halasz M., Polgar B., Poehlmann T.G., Markert U.R., Palkovics T., Keszei M., Par G., Kiss K., Szeberenyi J., Grama L., and Szekeres-Bartho J. Progesterone-induced blocking factor activates STAT6 via binding to a novel IL-4 receptor. J. Immunol. 176 (2006) 819-826
19. Liou H.C., and Baltimore D. Regulation of the NF-kappa B/rel transcription factor and I kappa B inhibitor system. Curr. Opin. Cell. Biol. 5 (1993) 477-487
20. Puthier D., Bataille R., and Amiot M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur. J. Immunol. 29 (1999) 3945-3950
21. Tu Y., Gardner A., and Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 60 (2000) 6763-6770
22. Hideshima T., Nakamura N., Chauhan D., and Anderson K.C. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20 (2001) 5991-6000
23. Hsu J.H., Shi Y., Frost P., Yan H., Hoang B., Sharma S., Gera J., and Lichtenstein A. Interleukin-6 activates phosphoinositol-3′ kinase in multiple myeloma tumor cells by signaling through RAS dependent and, separately, through p85-dependent pathways. Oncogene 23 (2004) 3368-3375
24. Podar K., Mostoslavsky G., Sattler M., Tai Y.T., Hayashi T., Catley L.P., Hideshima T., Mulligan R.C., Chauhan D., and Anderson K.C. Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J. Biol. Chem. 279 (2004) 21658-21665
25. Darnell J.E., Kerr I.M., and Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264 (1994) 1415-1421
26. Ihle J.N., and Kerr I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 11 (1995) 69-74
27. Shuai K., Stark G.R., Kerr I.M., and Darnell J.E. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 261 (1993) 1744-1746
28. Lutticken C., Wegenka U.M., Yuan J., Buschmann J., Schindler C., Ziemiecki A., Harpur A.G., Wilks A.F., Yasukawa K., Taga T., et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263 (1994) 89-92
29. Stahl N., Boulton T.G., Farruggella T., Ip N.Y., Davis S., Witthuhn B.A., Quelle F.W., Silvennoinen O., Barbieri G., Pellegrini S., et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263 (1994) 92-95
30. Narazaki M., Witthuhn B.A., Yoshida K., Silvennoinen O., Yasukawa K., Ihle J.N., Kishimoto T., and Taga T. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 2285-2289
31. Zhong Z., Wen Z., and Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264 (1994) 95-98
32. Gerhartz C., Heesel B., Sasse J., Hemmann U., Landgraf C., Schneider-Mergener J., Horn F., Heinrich P.C., and Graeve L. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130, I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J. Biol. Chem. 271 (1996) 12991-12998
33. Gronemeyer H., Gustafsson J.A., and Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev. Drug. Discov. 3 (2004) 950-964
34. Frisullo G., Nociti V., Iorio R., Katia Patanella A., Bianco A., Caggiula M., Sancricca C., Tonali P.A., Mirabella M., and Batocchi A.P. Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. Clin. Immunol. 124 (2007) 284-293
35. Wang L.H., Yang X.Y., Zhang X., and Farrar W.L. Nuclear receptors as negative modulators of STAT3 in multiple myeloma. Cell Cycle 4 (2005) 242-245
36. Nakashima J., Tachibana M., Horiguchi Y., Oya M., Ohigashi T., Asakura H., and Murai M. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6 (2000) 2702-2706
37. Ueda T., Bruchovsky N., and Sadar M.D. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J. Biol. Chem. 277 (2002) 7076-7085
38. Ueda T., Mawji N.R., Bruchovsky N., and Sadar M.D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 277 (2002) 38087-38094
39. Morelli L., Plotkin L., Leoni J., Fossati C., and Margni R. Analysis of oligosaccharides involved in the asymmetrical glycosylation of IgG monoclonal antibodies. Mol. Immunol. 30 (1993) 695-700
40. Bradford M.M. A rapid and sensitive method for the determination of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
41. Schaefer T.S., Sanders L.K., and Nathans D. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9097-9101
42. Szekeres-Barthó J., and Wegmann T.G. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J. Reprod. Immunol. 31 (1996) 81-95
43. Szereday L., Varga P., and Szekeres-Barthó J. Cytokine production in pregnancy. Am. J. Reprod. Immunol. 38 (1997) 418-422
44. Margni R.A., and Malan Borel I. Paradoxical behavior of asymmetric IgG antibodies. Immunol. Rev. 163 (1998) 77-87
45. Rawat R., Rainey G.J., Thompson C.D., Frazier-Jessen M.R., Brown R.T., and Nordan R.P. Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood 96 (2000) 3514-3521
46. Migone T.S., Lin J.X., Cereseto A., Mulloy J.C., O'Shea J.J., Franchini G., and Leonard W.J. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269 (1995) 79-81
47. Chaturvedi P., Sharma S., and Reddy E.P. Abrogation of interleukin-3 dependence of myeloid cells by the v-src oncogene requires SH2 and SH3 domains which specify activation of STATs. Mol. Cell. Biol. 17 (1997) 3295-3304
48. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., Matsumoto A., Tanimura S., Ohtsubo M., Misawa H., Miyazaki T., Leonor N., Taniguchi T., Fujita T., Kanakura Y., Komiya S., and Yoshimura A. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387 (1997) 921-924
49. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A., and Hilton D.J. A family of cytokine-inducible inhibitors of signaling. Nature 387 (1997) 917-921
50. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., Nishimoto N., Kajita T., Taga T., Yoshizaki K., Akira S., and Kishimoto T. Structure and function of a new STAT-induced STAT inhibitor. Nature 387 (1997) 924-929
51. Suzuki R., Sakamoto H., Yasukawa H., Masuhara M., Wakioka T., Sasaki A., Yuge K., Komiya S., Inoue A., and Yoshimura A. CIS3 JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells. Oncogene 17 (1998) 2271-2278
52. Terstegen L., Gatsios P., Bode J.G., Schaper F., Heinrich P.C., and Graeve L. The inhibition of interleukin-6-dependent STAT activation by mitogen-activated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130. J. Biol. Chem. 275 (2000) 18810-18817
53. Nicholson S.E., De Souza D., Fabri L.J., Corbin J., Willson T.A., Zhang J.G., Silva A., Asimakis M., Farley A., Nash A.D., Metcalf D., Hilton D.J., Nicola N.A., and Baca M. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6493-6498
54. Schmitz J., Weissenbach M., Haan S., Heinrich P.C., and Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275 (2000) 12848-12856
55. Szekeres-Bartho J., Polgar B., Kozma N., Miko E., Par G., Szereday L., Barakonyi A., Palkovics T., Papp O., and Varga P. Progesterone-dependent immunomodulation. Chem. Immunol. Allergy 89 (2005) 118-125
56. Canellada A., Färber A., Zenclussen A.C., Gentile T., Dokmetjian J., Keil A., Blois S., Miranda S., Gutiérrez G., Berod L., Markert U.R., and Margni R.A. Interleukin regulation of asymmetric IgG synthesis in isolated placental B cells. Am. J. Reprod. Immunol. 48 (2002) 275-283
57. Miranda S., Canellada A., Gentile T., and Margni R. Interleukin-6 and dexamethasone modulate in vitro asymmetric antibody synthesis and UDP-Glc glycoprotein glycosyltransferase activity. J. Reprod. Immunol. 66 (2005) 141-150